All News

The phase 2 Neo-CheckRay trial findings showed that adding durvalumab to radiation and chemotherapy nearly tripled pCR rates in PD-L1–negative ER+/HER2− breast cancer.

The FDA granted breakthrough therapy designation to olomorasib for previously treated, KRAS G12C-mutant advanced pancreatic cancer.

In a real-world CASCADE database analysis, prophylactic cranial irradiation was associated with a median overall survival of 29.8 months in limited-stage SCLC.

Ramy Sedhom, MD, blind-ranks landmark geriatric oncology and palliative care trials, picks his oncology Hall of Fame, and shares career advice on this episode of Double Blind.

Phase 1 trial data for cevostamab in multiple myeloma validate fixed-duration therapy as a “good concept,” according to Adam D. Cohen, MD.

Ajay K. Nooka, MD, MPH, FACP, says multiple myeloma treatment is entering an immunotherapy deluge, with more data on bispecifics ahead.

A novel alternative-salt capsule formulation of cabozantinib has received FDA tentative approval for advanced renal cell carcinoma, hepatocellular carcinoma, and neuroendocrine tumors.

Pirtobrutinib plus venetoclax/rituximab reduced the risk of progression or death by 45% among those with CLL in the phase 3 BRUIN CLL-322 trial.

Kay Yoon-Flannery, DO, spoke about how offering robotic mastectomy locally at AtlantiCare improved patient access.

Researchers have reported the first known case of TIL therapy in a patient with well-controlled HIV and metastatic melanoma.

Transplant-associated thrombotic microangiopathy GVHD are related, but distinct consequences of endothelial injury after allogeneic HCT.

Gedatolisib plus fulvestrant, with or without palbociclib, now holds NCCN Category 1 status for HR+/HER2– PIK3CA wild-type advanced breast cancer.

Ajay K. Nooka, MD, MPH, FACP, says the teclistamab-talquetamab combination reduced progression risk by 89% in MonumenTAL-6.

Kay Yoon-Flannery, DO, MPH, FACS, described why the lateral axillary line is her preferred incision site for single-port robotic mastectomy.

Frank McCormick, PhD, FRS, DSc (Hon), outlined the rationale for combining KRAS inhibitors with PI3K and checkpoint inhibitors to improve durability of response.

María Teresa Bourlon, MD, MSc, MS, discussed key kidney abstracts from the 2026 ASCO Meeting, including the LenCabo trial, the RAMPART trial, and the RADICAL trial.

Data from the PSMAddition trial support the approval of the radioligand-based regimen for this prostate cancer population.

Frank McCormick, PhD, FRS, DSc (Hon), discussed how RASolute-302 data showing daraxonrasib nearly doubled survival reshaped pancreatic cancer drug development.

Stay tuned for an in-depth discussion on navigating operational workflows and mitigating barriers to access for CAR T-cell therapy in multiple myeloma.

The regulatory decision for subcutaneous amivantamab in recurrent/metastatic head and neck squamous cell carcinoma was based on phase 1b/2 OrigAMI-4 data.

Two hematologic oncology experts discuss operational and referral workflows, as well as barriers to access for CAR T-cell therapy in multiple myeloma.

Selinexor maintenance therapy did not significantly improve PFS vs placebo in TP53 wild-type advanced or recurrent endometrial cancer in a phase 3 trial.

Kay Yoon-Flannery, DO, MPH, FACS, discusses da Vinci Single Port robotic mastectomy, ranging from technique and patient selection to outcomes.

Kay Yoon-Flannery, DO, MPH, FACS, explained how the da Vinci Single Port 3D visualization improves precision vs open or multiport surgery.

Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, MBA, predicts operational challenges as CAR T-cell therapy expands to non-oncology indications.

Frank McCormick, PhD, FRS, DSc (Hon), discussed his vision for preemptively treating KRAS-driven precancerous lesions, differences between KRAS allele subtypes, and where the field is headed over the next decade.

The FDA's CTGTAC voted 10-3 in favor RP1 plus nivolumab's benefit-risk profile in anti–PD-1–resistant advanced melanoma.

The UAE granted marketing authorization for nogapendekin alfa plus BCG in BCG-unresponsive NMIBC and with checkpoint inhibitors in metastatic NSCLC.

Data from a phase 1 trial validate FcRH5 as a “good target” in multiple myeloma therapy, according to Adam D. Cohen, MD.

Adding mFOLFOX6 and bevacizumab to atezolizumab cut the risk of progression or death by 58% vs atezolizumab alone in dMMR/MSI-H metastatic colorectal cancer.